Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: CMV RNA-Pulsed DC Vaccine for Glioblastoma
NCT04963413Phase 1Terminated
- Sponsor
- University of Florida
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pp65-flLAMP RNA-pulsed dendritic cell vaccine in glioblastoma (GBM), sponsored by University of Florida. Primary endpoint: Ability to generate CMV pp65 RNA-pulsed DCs in patients receiving adjuvant temozolomide chemotherapy after radiotherapy at 6 weeks. Started Jan 2022; status: terminated.
02
Drugs
pp65-flLAMP RNA-pulsed dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04963413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963413.